Aardvark Therapeutics, Inc. (AARD)
5.38
-0.35
(-6.11%)
USD |
NASDAQ |
Sep 04, 16:00
5.19
-0.19
(-3.53%)
After-Hours: 20:00
Aardvark Therapeutics Shareholders Equity (Quarterly) : 74.80M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.80M |
| March 31, 2026 | 86.99M |
| December 31, 2025 | 106.63M |
| September 30, 2025 | 122.38M |
| June 30, 2025 | 136.92M |
| March 31, 2025 | 150.69M |
| Date | Value |
|---|---|
| December 31, 2024 | 72.11M |
| September 30, 2024 | 80.58M |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | -34.80M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 597.21M |
| Corcept Therapeutics, Inc. | 705.78M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 84.97B |
| Eli Lilly & Co. | 33.88B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 81.46M |
| Total Liabilities (Quarterly) | 6.663M |
| Debt to Equity Ratio | 0.0091 |
| Current Ratio | 12.63 |
| Net Debt Paydown Yield | 0.01% |